Merck to Acquire Terns Pharmaceuticals

Editorial Analysis

Based on 1 source, 1 article

Merck's potential acquisition of Terns Pharmaceuticals signals a strategic move to strengthen its presence in the liver disease treatment market. Terns Pharmaceuticals has been developing innovative therapies for conditions like non-alcoholic steatohepatitis (NASH), a growing global health concern. The deal would provide Merck with access to Terns' pipeline of drug candidates and potentially accelerate the development of new treatments.